Cue Biopharma (CUE)
(Delayed Data from NSDQ)
$0.70 USD
-0.05 (-6.26%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $0.70 0.00 (0.57%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Cue Biopharma, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 49 | 76 | 64 | 85 | 59 |
Receivables | 2 | 0 | 3 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 1 | 1 |
Total Current Assets | 51 | 77 | 68 | 88 | 61 |
Net Property & Equipment | 1 | 2 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 3 | 3 | 3 | 3 |
Total Assets | 62 | 91 | 83 | 100 | 72 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 3 | 3 | 2 | 1 |
Current Portion Long-Term Debt | 4 | 2 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 4 | 5 | 3 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 0 | 1 | 7 | 4 |
Total Current Liabilities | 17 | 12 | 13 | 16 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 4 | 8 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 2 | 4 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 24 | 26 | 18 | 21 | 17 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 338 | 316 | 263 | 232 | 163 |
Retained Earnings | -301 | -250 | -197 | -153 | -109 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 37 | 66 | 65 | 79 | 55 |
Total Liabilities & Shareholder's Equity | 62 | 91 | 83 | 100 | 72 |
Total Common Equity | 37 | 66 | 65 | 79 | 55 |
Shares Outstanding | 45.10 | 43.00 | 31.70 | 30.20 | 22.90 |
Book Value Per Share | 0.82 | 1.53 | 2.07 | 2.61 | 2.38 |
Fiscal Year End for Cue Biopharma, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 41 | 49 | 55 | 58 |
Receivables | NA | 1 | 2 | 2 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 2 | 1 | 1 | 2 |
Total Current Assets | NA | 45 | 51 | 58 | 61 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 3 | 3 | 3 | 3 |
Total Assets | NA | 54 | 62 | 69 | 73 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 4 | 4 | 2 | 2 |
Current Portion Long-Term Debt | NA | 4 | 4 | 4 | 4 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 5 | 4 | 5 | 4 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 2 | 2 | 2 | 3 |
Total Current Liabilities | NA | 18 | 17 | 17 | 16 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 3 | 4 | 5 | 6 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 24 | 24 | 26 | 27 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 344 | 338 | 330 | 323 |
Retained Earnings | NA | -314 | -301 | -288 | -277 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 30 | 37 | 43 | 46 |
Total Liabilities & Shareholder's Equity | NA | 54 | 62 | 69 | 73 |
Total Common Equity | 0 | 30 | 37 | 43 | 46 |
Shares Outstanding | 48.60 | 48.60 | 45.10 | 44.90 | 43.10 |
Book Value Per Share | 0.00 | 0.62 | 0.82 | 0.95 | 1.07 |